Program
MK-2060
A development code.
Its studies are mostly in Kidney Failure, Chronic · Venous Thrombosis, led by Merck.
Furthest: phase 2, since Aug 26, 20217 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 70 open or running | phase 2since Aug 26, 2021 | Mar 12, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 12, 2019First study: phase 1 study in Kidney Failure, ChronicFirst studyNCT03873038 · 38 enrolled · United States
- Aug 26, 2021Phase 2 study in Kidney Failure, ChronicNCT05027074 · 506 enrolled · United States, Argentina, Australia and more
- Apr 12, 2022Phase 1 study in Kidney Failure, ChronicNCT05335005 · 12 enrolled · United States, Israel, Romania
- Dec 9, 2022Phase 1 study in Kidney Failure, ChronicNCT05656040 · 14 enrolled · United States
- Mar 3, 2023Phase 1 study in Kidney Failure, ChronicNCT05769595 · 17 enrolled · Japan
- Aug 30, 2024Phase 1 study in Venous ThrombosisNCT06582602 · 23 enrolled · United States
- Feb 19, 2025Phase 1 study in HealthyNCT06843993 · 36 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06843993Healthy · China | 1 | Completed | Oct 27, 2023 | 36 |
| NCT06582602Venous Thrombosis · United States | 1 | Completed | Apr 18, 2025 | 23 |
| NCT05769595Kidney Failure, Chronic · Japan | 1 | Completed | Feb 15, 2024 | 17 |
| NCT05656040Kidney Failure, Chronic · United States | 1 | Completed | Aug 12, 2024 | 14 |
| NCT05335005Kidney Failure, Chronic · United States, Israel, Romania | 1 | Completed | Feb 14, 2023 | 12 |
| NCT05027074Kidney Failure, Chronic · United States, Argentina, Australia and more | 2 | Completed | Oct 30, 2024 | 506 |
| NCT03873038Kidney Failure, Chronic · United States | 1 | Completed | Dec 20, 2021 | 38 |
How it is read
Names in the registry
- “MK-2060”, 7 entries
Codes read as this program: MK2060.
Conditions, from the studies’ own filings
- Kidney Failure, Chronic, 5 studies
- Venous Thrombosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.